Mallinckrodt debuts MR contrast injectors
Mallinckrodt has begun selling its Optistar MR contrast power injectors in the U.S. following FDA clearance of the device in December. Optistar is also being sold in Canada. St. Louis-based Mallinckrodt, which is working to become a single-source
Mallinckrodt has begun selling its Optistar MR contrast power injectors in the U.S. following FDA clearance of the device in December. Optistar is also being sold in Canada. St. Louis-based Mallinckrodt, which is working to become a single-source supplier for the contrast imaging market, estimates the annual market for power injectors to be around $35 million.
In related news, Mallinckrodt management is expanding its share repurchase program during the balance of this fiscal year (end-June) due to recent weakness in the companys stock price. So far this fiscal year, the company has repurchased 2.8 million shares of its stock at a market value of $90 million.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
